Vietnam.vn - Nền tảng quảng bá Việt Nam

Bidiphar sets revenue target of VND2,000 billion in 2025

Việt NamViệt Nam26/04/2025


Bidiphar sets revenue target of VND2,000 billion in 2025

(BD) - In 2025, Binh Dinh Pharmaceutical and Medical Equipment Joint Stock Company (Bidiphar) - one of the "giants" of the Vietnamese pharmaceutical industry, aims to increase its charter capital to VND 1,134 billion, revenue to VND 2,000 billion, and pre-tax profit to VND 335 billion.

The above target was approved by Bidiphar at the 2025 Annual General Meeting of Shareholders, which took place on the morning of April 26 (photo).

Photo: MH

Bidiphar identified that in 2025, the domestic and international context will still have many difficulties, with potential unpredictable factors. However, setting a revenue growth target higher than the results achieved in 2024 is based on many factors. In particular, it is important to take advantage of competitive advantages to continue to develop market share and revenue of key product groups such as cancer drugs, dialysis solutions, antibiotics, etc. Expanding the distribution system, distributing through diverse sales channels (hospitals, pharmacies, pharmacy chains, e-commerce, export, etc.).

At the same time, research and develop new products and improve existing products to promptly meet customer and market needs, create competitive advantages for the company and implement the criteria of taking quality as the foundation.

In addition, continue to optimize operations through new programs and new ways of doing things to bring higher efficiency at optimal costs. Optimize operations, perfect the operating model, organizational structure, create a foundation for applying new, modern, flexible and effective management and business models; redesign work processes, optimize operations based on technology applications, thereby optimizing personnel costs as well as operating costs...

Regarding the 2025 investment plan, Bidiphar continues to add more than 570 billion VND to the project of the small-volume sterile drug factory. Focusing on investment in digital transformation, production, research; building an office building at 34 Ngo May...

At the General Meeting of Shareholders, evaluating the results of production and business activities in 2024, Bidiphar has strived to achieve a revenue growth of 5% compared to the same period in 2023 and 91% of the yearly plan, equivalent to 1,817 billion VND. At the same time, it achieved a 2% growth in profit compared to the previous year, equivalent to 325 billion VND.

Bidiphar's 2025 General Meeting of Shareholders voted to approve a plan to pay dividends in shares at a rate of 20% for 2024.

MAI HOANG



Source: https://baobinhdinh.vn/viewer.aspx?macm=5&macmp=5&mabb=354998

Comment (0)

No data
No data

Same category

Visit U Minh Ha to experience green tourism in Muoi Ngot and Song Trem
Vietnam team promoted to FIFA rank after victory over Nepal, Indonesia in danger
71 years after liberation, Hanoi retains its heritage beauty in the modern flow
71st anniversary of Capital Liberation Day - stirring up the spirit for Hanoi to step firmly into the new era

Same author

Heritage

Figure

Enterprise

No videos available

News

Political System

Destination

Product